BioRestorative Therapies Appoints Crystal Romano as Head of Global Commercial Operations
New Appointment: BioRestorative Therapies has announced the addition of Crystal Romano to its management team.
Role and Responsibilities: Ms. Romano will lead the company's global commercial operations and innovation efforts.
Previous Experience: She previously served as Head of Innovation and Emerging Technologies at Cartessa.
Achievements: At Cartessa, she successfully brought over 11 new products and a biologics line to market in under two years.
Trade with 70% Backtested Accuracy
Analyst Views on BRTX

No data
About BRTX
About the author

Novo Nordisk (NVO) Gains 9.48% After FDA Approves Wegovy Obesity Pill
- FDA Approval Milestone: Novo Nordisk's once-daily Wegovy obesity pill received FDA approval, leading to a 9.48% increase in after-hours trading to $52.66, marking a significant advancement in obesity treatment that is expected to drive sales growth and enhance market competitiveness.
- Cardiovascular Risk Reduction: Wegovy is not only indicated for weight loss but also approved to reduce the risk of major cardiovascular events in obese patients, which will likely attract more patients with related conditions, thereby expanding the potential market.
- Rising Investor Interest: Despite no new updates, Neumora Therapeutics and BioRestorative Therapies saw increases of 16.02% and 6.90% respectively, indicating broad investor interest and optimism in the biotech sector, which may fuel a wave of investment across the industry.
- Clinical Trial Progress: IDEAYA Biosciences announced full enrollment of 435 patients in its Phase 2/3 trial, with progression-free survival data expected in Q1 2026, potentially paving the way for accelerated approval in the U.S. and further solidifying the company's position in cancer treatment.

NOTV and APLT Top After-Hours Biotech Gains; ALMS, TELA, CORT, and BRTX Also Show Progress
Biotech Gains in After-Hours Trading: Several small-cap biotech companies saw significant stock price increases in after-hours trading, driven by earnings updates and regulatory news.
Inotiv, Inc. Performance: Inotiv, Inc. experienced a 36.61% surge to $0.94 after announcing preliminary Q4 and full-year 2025 revenue projections, recovering from a prior decline.
Applied Therapeutics and Alumis Updates: Applied Therapeutics rose 16.89% following a positive earnings report, while Alumis advanced 7.09% despite a wider Q3 net loss, supported by collaboration income.
Regulatory Developments for BioRestorative: BioRestorative Therapies gained 8.06% after announcing a meeting with the FDA to discuss a potential accelerated pathway for its treatment of chronic lumbar disc disease.






